Artificial Intelligence2 years ago
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug discovery company, announces that AstraZeneca has selected an additional novel target for idiopathic pulmonary fibrosis (IPF)...